HIGH-VOLUME · BLOOD GLUCOSE INCREASED

exenatide Side Effects

exenatide (also sold as Byetta, Bydureon) is HIGH-VOLUME in this FAERS book #137 of 524 by FAERS report count. Signature opener: BLOOD GLUCOSE INCREASED - BLOOD GLUCOSE INCREASED leads at 15,472 reports (29.6% of the book).

Data updated 2026-05-15

52,302
FAERS reports

FAERS voluntary reports, 2005 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.

Among 52,302 FAERS reports for exenatide, BLOOD GLUCOSE INCREASED is the most-reported reaction (15,472). Volume band HIGH-VOLUME #137 of 524 by FAERS report count.

High-report extract for exenatide (Byetta): 52,302 FAERS rows (2005-2025). Top named reactions: BLOOD GLUCOSE INCREASED, WEIGHT DECREASED, NAUSEA. Outcome stamps DEATH-MARKED · HOSP-MID · SEX-BALANCED. FAERS is voluntary signal detection, not incidence.

Counts from the openFDA FAERS extract (2005–2025). Stamps CASELOAD · DEATH-MARKED · HOSP-MID · SEX-BALANCED.

BLOOD GLUCOSE INCREASED leads 15,472 of 52,302 reports

BLOOD GLUCOSE INCREASED
15,472
WEIGHT DECREASED
12,125
NAUSEA
12,040
DECREASED APPETITE
5,643
BLOOD GLUCOSE DECREASED
5,517
VOMITING
4,345
DIARRHOEA
2,742
DIZZINESS
2,673
HEADACHE
2,086
INJECTION SITE PAIN
2,023
PANCREATITIS
2,012
INJECTION SITE BRUISING
1,843
INJECTION SITE HAEMORRHAGE
1,809
FATIGUE
1,759
FEELING ABNORMAL
1,664
INCORRECT DOSE ADMINISTERED
1,631
MALAISE
1,596
ASTHENIA
1,540
DRUG EFFECT DECREASED
1,525

Who reports · age peak 45-64 (SEX-BALANCED)

Sex coding · SEX-BALANCED

Female 32,746 (64%)
Male 18,369 (36%)
Unknown 209

Age peak 45-64 (20,550 reports)

0-17 50 (0%)
18-44 3,015 (9%)
45-64 20,550 (58%)
65-74 9,220 (26%)
75+ 2,393 (7%)

Reporting taper since 2005 peak

2005 2025

Reactions in Death Reports

Death appears on 1,762 reports (3.4% - MARKED). Reactions below co-occur in those rows only.

Reaction Reports
PANCREATIC CARCINOMA 765
DEATH 346
PANCREATIC CARCINOMA METASTATIC 268
METASTASES TO LIVER 178
RENAL FAILURE 94
PANCREATITIS 91
ADENOCARCINOMA PANCREAS 90
NAUSEA 82
WEIGHT DECREASED 77
HYPERTENSION 74
JAUNDICE CHOLESTATIC 65
METASTASES TO LUNG 64
MYOCARDIAL INFARCTION 60
PANCREATITIS ACUTE 60
VOMITING 58
ASCITES 53
ACUTE KIDNEY INJURY 52
METASTASES TO LYMPH NODES 51
CHOLELITHIASIS 45
BLADDER CANCER 44

Reactions in Hospitalization Reports

Hospitalization mid-share (7,532, 14.4%). Co-reported reactions:

Reaction Reports
WEIGHT DECREASED 1,332
NAUSEA 1,199
BLOOD GLUCOSE INCREASED 1,150
PANCREATITIS 1,033
VOMITING 813
PANCREATITIS ACUTE 574
DIARRHOEA 483
DECREASED APPETITE 481
BLOOD GLUCOSE DECREASED 431
DEHYDRATION 377
RENAL FAILURE 360
DIZZINESS 333
FALL 331
ABDOMINAL PAIN 329
DYSPNOEA 325
RENAL FAILURE ACUTE 306
ASTHENIA 296
MYOCARDIAL INFARCTION 272
MALAISE 271
How to read exenatide FAERS figures (CASELOAD · DEATH-MARKED · HOSP-MID)

FAERS holds 52,302 voluntary reports linked to exenatide (Byetta, Bydureon), 2005-2025. Death is listed on 1,762 (3.4%). Hospitalization appears on 7,532 (14.4%). Top co-reported indication: Type 2 Diabetes Mellitus.

CASELOAD books overweight common drugs and loud reporting cultures; BLOOD GLUCOSE INCREASED is the page opener, not a per-patient risk.

Read with exenatide

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.